Illumina focuses on molecular diagnostics

San Diego-based Illumina has created two new business units. The Life Sciences Business Unit will include all products and services related to the company's sequencing and genotyping business. And with the new Diagnostics Business Unit, Illumina will attempt to tap into the hot molecular diagnostics market.

"This new organizational structure provides the foundation to continue scaling our global operations...A specific result will be the acceleration of the integration of our sequencing and genotyping technologies. Additionally, it will enable us to put more focus on developing our diagnostics business," said Jay Flatley, Illumina's President and CEO. The company also announced a number of management changes, and said that it's now in search of a product development VP and an operations VP.

- see Illumina's release for more

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.